Richard T Moxley 3rd
Overview
Explore the profile of Richard T Moxley 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamel J, McDermott M, Hilbert J, Martens W, Luebbe E, Tawil R, et al.
Muscle Nerve
. 2022 Jul;
66(4):508-512.
PMID: 35778789
Introduction/aims: Disease progression in myotonic dystrophy (DM) is marked by milestone events when functional thresholds are crossed. DM type 2 (DM2) is considered less severe than DM type 1 (DM1),...
2.
Deutsch G, Hagerman K, Sampson J, Dent G, Dekdebrun J, Parker D, et al.
Muscle Nerve
. 2022 Feb;
65(5):560-567.
PMID: 35179228
Introduction/aims: Myotonic dystrophy type 1 (DM1) is known to affect cognitive function, but the best methods to assess central nervous system involvement in multicenter studies have not been determined. In...
3.
Hunter M, Ekstrom A, Campbell C, Hung M, Bounsanga J, Bates K, et al.
Muscle Nerve
. 2019 Jul;
60(4):392-399.
PMID: 31298737
Introduction: The prevalence and impact of symptoms affecting individuals with pediatric forms of myotonic dystrophy type-1 (DM1) are not well understood. Methods: Patients from the United States, Canada, and Sweden...
4.
Hilbert J, Thornton C, Moxley 3rd R
Neurology
. 2018 Apr;
90(17):814.
PMID: 29686124
No abstract available.
5.
Hilbert J, Barohn R, Clemens P, Luebbe E, Martens W, McDermott M, et al.
Neurology
. 2017 Sep;
89(13):1348-1354.
PMID: 28855409
Objective: To analyze gastrointestinal (GI) manifestations, their progression over time, and medications being used to treat GI symptoms in a large cohort of patients with myotonic dystrophy types 1 (DM1)...
6.
Griggs R, Miller J, Greenberg C, Fehlings D, Pestronk A, Mendell J, et al.
Neurology
. 2016 Aug;
87(20):2123-2131.
PMID: 27566742
Objective: To assess safety and efficacy of deflazacort (DFZ) and prednisone (PRED) vs placebo in Duchenne muscular dystrophy (DMD). Methods: This phase III, double-blind, randomized, placebo-controlled, multicenter study evaluated muscle...
7.
Topaloglu H, Gloss D, Moxley 3rd R, Ashwal S, Oskoui M
Neurology
. 2016 Jul;
87(2):238.
PMID: 27402942
No abstract available.
8.
Gloss D, Moxley 3rd R, Ashwal S, Oskoui M
Neurology
. 2016 Feb;
86(5):465-72.
PMID: 26833937
Objective: To update the 2005 American Academy of Neurology (AAN) guideline on corticosteroid treatment of Duchenne muscular dystrophy (DMD). Methods: We systematically reviewed the literature from January 2004 to July...
9.
Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert J, et al.
Neurology
. 2015 Nov;
85(24):2136-46.
PMID: 26581301
Objective: To determine the frequency and relative importance of the most life-affecting symptoms in myotonic dystrophy type 2 (DM2) and to identify the factors that have the strongest association with...
10.
Johnson N, Ekstrom A, Campbell C, Hung M, Adams H, Chen W, et al.
Dev Med Child Neurol
. 2015 Oct;
58(7):698-705.
PMID: 26510705
Aim: The frequency and impact of symptoms experienced by patients with congenital, childhood, and juvenile-onset myotonic dystrophy (CDM/ChDM/JDM) is not documented. This report identifies symptomatic areas with the greatest disease...